Square Pharmaceuticals PlcDSEBD: SQURPHARMA

SQURPHARMA: Net revenue grew 21.7% and net profit after tax rose 21.5% year-over-year in Q1 FY2025-26

· Issued by Square Pharmaceuticals Plc

Q1 FY2025-26 saw net revenue rise 21.7% year-over-year to Tk. 21.59 billion and net profit after tax up 21.5% to Tk. 7.40 billion. EPS increased to Tk. 8.35, with strong cash flow and asset growth, reflecting robust recovery and business momentum.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Company analysis

Earlier from Square Pharmaceuticals

All Square Pharmaceuticals news releases